Lyra Therapeutics (LYRA) AI Stock Analysis

• Market Cap: $7.08M
• Dividend Yield: N/A
• Average Volume (3M): 5.54M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: -29.46%
• EPS Growth: 2.71%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 66,267,230
• 10 Day Avg. Volume: 12,315,007
• 30 Day Avg. Volume: 5,535,336
• PEG Ratio: -0.02
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: 1718.18% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

Lyra Therapeutics faces significant financial and technical challenges, reflected in its low score. Persistent losses and negative cash flows highlight financial instability, while bearish technical indicators suggest continued downward pressure on the stock. The negative P/E ratio and lack of dividend yield further underscore the valuation concerns. Strategic adjustments are essential to improve the company's financial position and investor appeal.

Positive Factors

Financial Performance

LYRA reported EPS of $(0.18) versus consensus of $(0.22), showing better than expected financial performance.

Regulatory Alignment

LYRA has gained alignment with the FDA around a potential Phase 3 trial design including co-primary endpoints and inclusion criteria.

Negative Factors

Regulatory Uncertainty

There is a current lack of clarity around an approval path for LYR-210 and uncertainty around the outcome of the ENLIGHTEN II trial.

Trial Results

ENLIGHTEN I missed its primary endpoint, indicating increased risk for the ENLIGHTEN II readout.

Lyra Therapeutics Business Overview & Revenue Model

Company Description

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Lyra Therapeutics makes money through the development and commercialization of its proprietary drug-eluting implant products. The company's revenue model primarily hinges on bringing its therapeutic solutions to market, targeting partnerships with pharmaceutical companies for distribution and co-development. Lyra seeks to generate revenue through product sales, licensing agreements, and potential collaborations with other entities in the healthcare and pharmaceutical sectors. Additionally, Lyra may engage in strategic partnerships or joint ventures to expand its market reach and expedite the commercialization of its therapies. Revenue generation is largely dependent on successful clinical trials, regulatory approvals, and market adoption of its products.

Lyra Therapeutics Financial Statement Overview

Summary

Lyra Therapeutics is facing financial challenges, with consistent losses and negative cash flows. The biotechnology industry often requires substantial investment, but the company's high leverage and shrinking equity base pose risks. While there are strengths in operational cash efficiency, overall financial health is concerning, necessitating strategic adjustments to improve profitability and reduce reliance on external funding.

Income Statement

Lyra Therapeutics has experienced a decrease in total revenue from $1,558,000 in 2023 to $1,534,000 in 2024. The net profit margin remains negative, reflecting ongoing losses. Despite revenue growth in prior years, the company struggles with high operating losses, as evidenced by the negative EBIT and EBITDA margins.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating higher leverage, but remains manageable. Stockholders' equity has decreased significantly, suggesting potential financial instability. Despite a high equity ratio, the reduction in total assets and equity raises concerns about long-term sustainability.

Cash Flow

Lyra has a negative free cash flow, indicating cash outflows exceeding inflows. Operating cash flow remains negative, though there is a high operating cash flow to net income ratio, reflecting cash efficiency in operations. However, the reliance on financing activities for cash inflows indicates a need for external funding.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.47M	1.53M	1.56M	1.36M	285.00K	0.00
	Gross Profit
-12.01M	1.53M	1.56M	296.00K	-716.00K	-95.00K
	EBIT
-101.42M	-96.35M	-67.12M	-56.31M	-43.62M	-22.21M
	EBITDA
-67.04M	-96.35M	-65.25M	-53.92M	-42.61M	-22.11M
	Net Income Common Stockholders
-97.61M	-93.44M	-62.68M	-55.28M	-42.41M	-22.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.89M	40.58M	102.75M	97.89M	45.75M	74.59M
	Total Assets
0.00	66.35M	142.60M	109.97M	54.87M	80.83M
	Total Debt
0.00	34.38M	26.88M	2.22M	1.45M	2.44M
	Net Debt
23.89M	-6.20M	4.53M	-30.33M	-44.29M	-72.15M
	Total Liabilities
0.00	54.75M	53.18M	29.21M	20.55M	6.34M
	Stockholders Equity
23.28M	11.59M	89.42M	80.75M	34.32M	74.49M
Cash Flow		Free Cash Flow
-80.90M	-72.35M	-64.35M	-43.55M	-29.20M	-22.92M
	Operating Cash Flow
-77.72M	-70.01M	-63.30M	-43.38M	-25.82M	-21.14M
	Investing Cash Flow
49.81M	80.31M	-12.58M	-65.01M	-3.38M	-1.77M
	Financing Cash Flow
27.45M	8.53M	65.69M	96.26M	359.00K	87.70M

Lyra Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.11
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYRA, the sentiment is Neutral. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.12, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.47 is Neutral, neither overbought nor oversold. The STOCH value of 25.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LYRA.

Lyra Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.19B	3.04	-44.64%	2.82%	16.45%	-0.53%
LYRA	42 Neutral	$7.08M	―	-195.46%	―	-29.46%	2.71%
BCLI	40 Underperform	$10.80M	―	234.90%	―	―	62.35%
SPRB	35 Underperform	$2.74M	―	-135.33%	―	-51.32%	-1.76%
GTBP	34 Underperform	$5.79M	―	-538.87%	―	―	-26.02%

Lyra Therapeutics Corporate Events

Lyra Therapeutics Announces Reverse Stock Split Decision

On May 14, 2025, Lyra Therapeutics held its Annual Meeting of Stockholders where key decisions were made, including the election of two Class II Directors and the approval of a reverse stock split. The reverse stock split, set at a ratio of 1-for-50, will become effective on May 27, 2025, with trading on a split-adjusted basis commencing on May 28, 2025. This strategic move is aimed at consolidating shares to potentially enhance the stock’s marketability and meet trading requirements.

The most recent analyst rating on (LYRA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.

Spark’s Take on LYRA Stock

According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.

Lyra Therapeutics faces significant financial and technical challenges, reflected in its low score. Persistent losses and negative cash flows highlight financial instability, while bearish technical indicators suggest continued downward pressure on the stock. The negative P/E ratio and lack of dividend yield further underscore the valuation concerns. Strategic adjustments are essential to improve the company’s financial position and investor appeal.

To see Spark’s full report on LYRA stock, click here.